# Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

> **NCT03672643** · PHASE4 · TERMINATED · sponsor: **Pfizer** · enrollment: 41 (actual)

## Conditions studied

- ALK or ROS1-positive NSCLC

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT03672643
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-28
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** The trial is terminated based on business decision, not due to safety concerns or regulatory requirements.
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03672643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03672643, "Long Term Safety Observation of Crizotinib in Chinese NSCLC Population". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03672643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*